Pancreatic Cancer Research

ResearcherUniversity of PisaNo recent work listed

Angelo Andriulli

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8862-7083; OpenAlex author ID A5015267957. Sources: OpenAlex.

Their work

Papers
22 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
55
Papers, trials and grants by year

2012: 3 papers · 2013: 2 papers · 2014: 1 paper · 2015: 1 paper · 2016: 3 papers · 2017: none · 2018: 4 papers · 2019: 2 papers · 2020: 3 papers · 2021: 3 papers

Papers 22

  1. Genome-wide scan of long noncoding RNA single nucleotide polymorphisms and pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.33475↗
  2. Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/carcin/bgab057↗
  3. Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. Co-author DOI 10.3389/fonc.2021.771312↗
  4. Genome-wide association study identifies an early onset pancreatic cancer risk locus. Co-author DOI 10.1002/ijc.33004↗
  5. Clinical Significance of Circulating miR-1273g-3p and miR-122-5p in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2020.00044↗
  6. Early-Onset Diabetes as Risk Factor for Pancreatic Cancer: miRNA Expression Profiling in Plasma Uncovers a Role for miR-20b-5p, miR-29a, and miR-18a-5p in Diab… Last author DOI 10.3389/fonc.2020.01567↗
  7. Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study. Co-author DOI 10.1002/ijc.31928↗
  8. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.32127↗
  9. Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation. Co-author DOI 10.1002/ijc.31047↗
  10. Influence of gemcitabine chemotherapy on the microbiota of pancreatic cancer xenografted mice. Co-author DOI 10.1007/s00280-018-3549-0↗
  11. Droplet digital PCR quantification of miR-1290 as a circulating biomarker for pancreatic cancer. Last author DOI 10.1038/s41598-018-34597-z↗
  12. Common genetic variants associated with pancreatic adenocarcinoma may also modify risk of pancreatic neuroendocrine neoplasms. Co-author DOI 10.1093/carcin/bgx150↗
  13. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Co-author DOI 10.18632/oncotarget.10935↗
  14. Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites. Co-author DOI 10.18632/oncotarget.6808↗
  15. Development of a metabolites risk score for one-year mortality risk prediction in pancreatic adenocarcinoma patients. Co-author DOI 10.18632/oncotarget.7108↗
  16. SIRT1 and circadian gene expression in pancreatic ductal adenocarcinoma: Effect of starvation. Co-author DOI 10.3109/07420528.2014.1003351↗
  17. Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clini… Co-author DOI 10.1186/s12967-014-0248-4↗
  18. Genetic susceptibility to pancreatic cancer and its functional characterisation: the PANcreatic Disease ReseArch (PANDoRA) consortium. Co-author DOI 10.1016/j.dld.2012.09.014↗
  19. Neoadjuvant chemo-radiotherapy for patients with borderline resectable pancreatic cancer: a meta-analytical evaluation of prospective studies. First author DOI 10.6092/1590-8577/1724↗
  20. Correlations among PPARγ, DNMT1, and DNMT3B Expression Levels and Pancreatic Cancer. Co-author DOI 10.1155/2012/461784↗
  21. Time-Qualified Patterns of Variation of PPARγ, DNMT1, and DNMT3B Expression in Pancreatic Cancer Cell Lines. Co-author DOI 10.1155/2012/890875↗
  22. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Co-author DOI 10.1245/s10434-011-2110-8↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Francesca Tavano · 10 shared papers, 2012–2020 · strength 0.58
  2. Andrea Fontana · 8 shared papers, 2012–2020 · strength 0.52
  3. Tommaso Mazza · 4 shared papers, 2016–2020 · strength 0.34
  4. Valerio Pazienza · 7 shared papers, 2012–2018 · strength 0.33
  5. Evaristo Maiello · 3 shared papers, 2014–2020 · strength 0.22
  6. Pierluigi Di Sebastiano · 6 shared papers, 2012–2015 · strength 0.19
  7. Fabio F. di Mola · 4 shared papers, 2012–2015 · strength 0.14
  8. Concetta Panebianco · 2 shared papers, 2015–2018 · strength 0.12
  9. Iole Maria Di Gangi · 2 shared papers, 2016 · strength 0.11
  10. Kaarel Adamberg · 1 shared paper, 2018 · strength 0.08
  11. Tiziana Pia Latiano · 1 shared paper, 2018 · strength 0.08
  12. Paola Fogar · 2 shared papers, 2013–2018 · strength 0.08
  13. Maria Gazouli · 2 shared papers, 2013–2018 · strength 0.08
  14. Federico Canzian · 2 shared papers, 2013–2018 · strength 0.08
  15. Niccola Funel · 2 shared papers, 2013–2018 · strength 0.08
  16. Renata Talar‐Wojnarowska · 2 shared papers, 2013–2018 · strength 0.08
  17. Ewa I. Malecka-Panas · 2 shared papers, 2013–2018 · strength 0.08
  18. John P. Neoptolemos · 2 shared papers, 2013–2018 · strength 0.08
  19. Gabriele Capurso · 2 shared papers, 2013–2018 · strength 0.08
  20. Daniele Campa · 2 shared papers, 2013–2018 · strength 0.08
  21. Stefano Landi · 2 shared papers, 2013–2018 · strength 0.08
  22. William Greenhalf · 2 shared papers, 2013–2018 · strength 0.08
  23. Daniela Basso · 2 shared papers, 2013–2018 · strength 0.08
  24. Lucia Lombardi · 2 shared papers, 2014–2015 · strength 0.08
  25. Virginia Festa · 2 shared papers, 2012–2013 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.